Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fate Therapeutics, Inc. (FATE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fate Therapeutics is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market, and its Exchange Act reports offer detailed information on financial condition, clinical programs, and corporate actions related to its iPSC-derived cellular immunotherapy pipeline.
Among the key documents available are current reports on Form 8-K, where Fate Therapeutics reports material events such as quarterly financial results, corporate restructuring decisions, clinical data updates, and executive appointments. For example, recent 8-K filings describe financial results for specific quarters, a restructuring that includes a workforce reduction to streamline operations and extend cash runway, and detailed summaries of new and updated FT819 clinical data presented at scientific meetings. Other 8-K filings outline changes in board composition and the appointment of a Chief Financial Officer, including associated compensation terms and inducement equity awards.
Investors can also use SEC filings to confirm the company’s trading status, as Fate Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market under the symbol FATE. Filings disclose the company’s principal executive office location by city and state, the par value of its common stock, and the use of inducement equity plans under Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, each new Fate Therapeutics filing is captured from EDGAR and paired with AI-powered summaries that highlight the most important points, such as clinical milestones, restructuring charges, or changes in leadership. Users can quickly scan Form 8-K items, then drill down into the full text for deeper analysis, helping them understand how regulatory disclosures relate to the company’s iPSC-derived CAR T-cell and NK-cell development strategy.
Fate Therapeutics (FATE)10/20/2025. The CFO was granted 75,000 restricted stock units at $0.00, which vest 25% on November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029. The CFO also received a stock option for 375,000 shares at an exercise price of $1.54, vesting 25% on October 20, 2026 and monthly thereafter for 36 months, expiring on October 20, 2035. Following the transactions, the filing lists 75,000 common shares and 375,000 options beneficially owned.
Fate Therapeutics (FATE) filed a Form 3, the initial statement of beneficial ownership for its Chief Financial Officer under Section 16. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/20/2025. The form was filed by one reporting person, with a Power of Attorney on file (Exhibit 24) and signed by Cindy Tahl, as Attorney-in-Fact on 10/21/2025.
Fate Therapeutics filed a Form S-8 to register 1,750,000 additional shares of common stock for issuance under its Amended and Restated Inducement Equity Plan.
The Board approved the increase on October 13, 2025, adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The filing uses General Instruction E to register additional securities and incorporates the prior S-8 (File No. 333-253459).
Pursuant to Rule 416(a), the registration also covers an indeterminate number of additional shares for anti‑dilution and other adjustments.
Fate Therapeutics (FATE) reported board and leadership changes. On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian notified the company of their resignations from the Board, effective October 13, 2025. The company stated both resignations were voluntary and not due to any disagreement on operations, practices, or policies. Following these changes, the Board size was reduced from 10 to 8 directors, effective October 13, 2025.
On October 13, 2025, the Board approved the appointment of Kamal Adawi, M.S., M.B.A., as Chief Financial Officer, effective October 20, 2025. He was also designated principal financial officer and principal accounting officer, replacing Bahram Valamehr in those roles; Dr. Valamehr continues as Director and as President and Chief Executive Officer. The company furnished a press release on October 14, 2025 announcing Mr. Adawi’s appointment.
Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they collectively hold 2,274,020.09 shares of Fate Therapeutics common stock, representing 2.0% of the class. The cover pages report shared voting power of 2,273,623.09 shares and shared dispositive power of 2,274,020.09 shares.
The filing includes a joint filing agreement (Exhibit 99.1) and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. (Exhibit 99.2). The filing further certifies the securities are held in the ordinary course of business and not for the purpose of changing control. The statement is signed by Veronica Mupazviriwo as attorney-in-fact on behalf of both reporting persons.
Fate Therapeutics (FATE) reported that on August 7, 2025 its Board approved a corporate restructuring to streamline operations, reduce operating expenses and extend the company’s cash runway. The company committed to a reduction in total workforce of approximately 12% and informed affected employees on August 12, 2025.
The company expects the reduction-in-force to complete in the third quarter of 2025 and estimates it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs. A press release with the quarter-end results is attached as Exhibit 99.1, and the information is furnished, not filed, under the Exchange Act.